Insulin Resistance in Women With Prolactinoma

Universidade Federal do Rio de Janeiro2,004 enrolled

Overview

Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma. The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.

A cross-sectional study was performed in non-obese premenopausal women with prolactinoma treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG). They were compared with control women of similar age and BMI distribution.

Study Type

OBSERVATIONAL

Enrollment

2,004

Conditions

Prolactinoma Insulin Resistance Hyperlipidemia

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 48 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Prolactinoma * Female gender * Premenopausal Exclusion Criteria: * Obesity (BMI ≥ 30 kg/m²) * Diabetes mellitus * Hypertension * GH deficiency * Hypothyroidism * Primary hypogonadism * Adrenal insufficiency * Pituitary surgery

Locations (1)

Clementino Fraga Filho University Hospital

Rio de Janeiro, Rio de Janeiro, Brazil

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.